Journal Article

Lethal pulmonary thromboembolism in mice induced by intravenous human umbilical cord mesenchymal stem cell-derived large extracellular vesicles in a dose- and tissue factor-dependent manner

Yang, Bian-lei, Li, He, Yu, Ya-li, Ren, Wen-xiang, Xu, Liu-yue, Wu, Di, Long, Yao-ying, Li, Qiu-bai, Chen, Zhi-chao, Zhang, An-yuan, Gao, Fei, Wang, Hong-xiang, Qu, Jiao, Cao, Yu-lin, Lei, Qian, Wang, Shan

2024

Overview

Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have obvious advantages over MSC therapy. But the strong procoagulant properties of MSC-EVs pose a potential risk of thromboembolism, an issue that remains insufficiently explored. In this study, we systematically investigated the procoagulant activity of large EVs derived from human umbilical cord MSCs (UC-EVs) both in vitro and in vivo. UC-EVs were isolated from cell culture supernatants. Mice were injected with UC-EVs (0.125, 0.25, 0.5, 1, 2, 4 μg/g body weight) in 100 μL PBS via the tail vein. Behavior and mortality were monitored for 30 min after injection. We showed that these UC-EVs activated coagulation in a dose- and tissue factor-dependent manner. UC-EVs-induced coagulation in vitro could be inhibited by addition of tissue factor pathway inhibitor. Notably, intravenous administration of high doses of the UC-EVs (1 μg/g body weight or higher) led to rapid mortality due to multiple thrombus formations in lung tissue, platelets, and fibrinogen depletion, and prolonged prothrombin and activated partial thromboplastin times. Importantly, we demonstrated that pulmonary thromboembolism induced by the UC-EVs could be prevented by either reducing the infusion rate or by pre-injection of heparin, a known anticoagulant. In conclusion, this study elucidates the procoagulant characteristics and mechanisms of large UC-EVs, details the associated coagulation risk during intravenous delivery, sets a safe upper limit for intravenous dose, and offers effective strategies to prevent such mortal risks when high doses of large UC-EVs are needed for optimal therapeutic effects, with implications for the development and application of large UC-EV-based as well as other MSC-EV-based therapies.

• Publisher: Springer Nature Singapore,Nature Publishing Group
• Subject: Animals / Anticoagulants / Biomedical and Life Sciences / Biomedicine / Blood Coagulation - drug effects / Body weight / Cell culture / Coagulation / Dose-Response Relationship, Drug / Extracellular vesicles / Extracellular Vesicles - metabolism / Fibrinogen / Heparin / Humans / Immunology / Internal Medicine / Intravenous administration / Male / Medical Microbiology / Mesenchymal stem cells / Mesenchymal Stem Cells - metabolism / Mice / Mice, Inbred C57BL / Mortality / Pharmacology/Toxicology / Prothrombin / Pulmonary Embolism - metabolism / Stem cells / Thromboembolism / Thromboplastin / Thromboplastin - metabolism / Thrombosis / Tissue factor / Umbilical cord / Umbilical Cord - cytology / Vaccine